|
|||||
|
|
Evaluation of a New Chemotherapeutic Agent in Patients with "Advanced Refractory" Acute Leukemia. Studies of 6-Azauracil |
|
| Authors: | FREIREICH, EMIL J. FREI, EMIL, III HOLLAND, JAMES F. PINKEL, DONALD SELAWRY, OLEG ROTHBERG, HARVEY HAURANI, FARID TAYLOR, ROBERT GEHAN, EDMUND A. |
| Affiliation: | 1 National Cancer institute, Bethesda. Md. 2 Roswell Park Memorial Institute, Buffalo. N. Y. 3 Walter Reed Army Hosptial, Washington, D. C. 4 Jefferson Medical College, Philadelphia, Pa. |
| Abstract: | 6-Azauracil was studied in patients with "advanced" acute leukemia, refractory to standard chemotherapy. Under the conditions of the study thiscompound was found to have no significant antileukemic activity. As a result,these data have defined the natural history of this phase of acute leukemia. Asignificant proportion (30 per cent) of these patients showed objective hematologic improvement even in the absence of effective specific therapy, whichmight be ascribed to a prospective new agent. The median survival from theonset of the study of this group of patients was two months, and survivalpatterns for adults and children were similar. Submitted on December 23, 1959 Accepted on February 20, 1960 |
| Keywords: | |
| 点击此处可从《Blood》浏览原始摘要信息 | |
| 点击此处可从《Blood》下载全文 | |